Amplistar
This article was originally published in The Gray Sheet
Executive Summary
Development of ovarian cancer-screening technologies will be funded by planned $15 mil. equity financing being arranged by financial advisor First Union Securities, the firm reports Oct. 9. The Winston-Salem, North Carolina start-up is focusing on discovery of unique tumor specific antibodies, especially ovarian carcinoma. The firm has discovered 28 antibody targets in all to screen for ovarian, colon, prostate, lung and breast cancer using both genomic and functional genomic information